Format

Send to

Choose Destination
Nature. 2002 Jan 10;415(6868):234-9.

Myocardial gene therapy.

Author information

1
Department of Medicne, St. Elizabeth's Medical Center, Tufts School of Medicine, Boston, MA 02135, USA.

Abstract

Gene therapy is proving likely to be a viable alternative to conventional therapies in coronary artery disease and heart failure. Phase 1 clinical trials indicate high levels of safety and clinical benefits with gene therapy using angiogenic growth factors in myocardial ischaemia. Although gene therapy for heart failure is still at the pre-clinical stage, experimental data indicate that therapeutic angiogenesis using short-term gene expression may elicit functional improvement in affected individuals.

PMID:
11805848
DOI:
10.1038/415234a
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center